We’re pleased to share the news of IQ-EQ’s involvement in a new financing agreement between French biotech company Nanobiotix and U.S. investment firm HealthCare Royalty (HCRx), supporting Nanobiotix’s further clinical development of a new innovative oncology product.
Nanobiotix is an advanced clinical-stage biotechnology company in France, pioneering physics-based approaches to expand treatment options for patients with cancer or other diseases. HCRx specialises in acquiring royalty sharing opportunities for commercial or near-commercial biopharmaceutical products and has already invested over USD 5 billion in more than 90 biopharmaceutical products since its inception.
As part of the ongoing clinical development of an innovative JNJ-1900 (NBTXR3) potential cancer treatment, Nanobiotix has entered into a non-dilutive financing agreement for royalty sharing and milestone payments with HCRx, providing Nanobiotix with MUSD 50 upon signing and the possibility of an additional investment of up to MUSD 21 based on the achievement of objectives at the end of a twelve-month period.
IQ-EQ’s AMF-approved management company, IQ EQ Management, has acted as fiduciaire and set up a fiducie-gestion (management trust) to organise the receipt and distribution of royalties and milestones relating to the license granted to Janssen Pharmaceutica (Johnson & Johnson group) for JNJ-1900 (NBTXR3) among beneficiaries Nanobiotix, HCRx funds and the European Investment Bank (EIB).
This transaction highlights the fiducie’s ability to establish itself as an efficient and adaptable legal mechanism, ensuring strict execution of revenue sharing from the license agreement provisions related to JNJ-1900 (NBTXR3) between Nanobiotix, HCRx funds and the EIB.
Leader and pioneer in fiduciary services in France since 2008, IQ EQ Management has set up and managed more than 500 fiducies, covering all types of assets. Click here to find out more about our fiducie services.
